Benitec Biopharma (NASDAQ:BNTC) Earns Buy Rating from Analysts at TD Cowen

Analysts at TD Cowen initiated coverage on shares of Benitec Biopharma (NASDAQ:BNTC - Get Free Report) in a research report issued on Monday, MarketBeat.com reports. The brokerage set a "buy" rating on the biotechnology company's stock.

Several other research analysts have also recently commented on the company. HC Wainwright reissued a "buy" rating and set a $28.00 price target on shares of Benitec Biopharma in a research report on Monday, May 19th. JMP Securities reissued a "market outperform" rating and set a $20.00 price target on shares of Benitec Biopharma in a research report on Thursday, May 15th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Benitec Biopharma has an average rating of "Buy" and a consensus target price of $23.83.

Benitec Biopharma Stock Up 2.4%

NASDAQ BNTC traded up $0.32 during trading hours on Monday, hitting $13.49. 129,261 shares of the company traded hands, compared to its average volume of 56,242. The business's 50-day moving average is $14.27 and its 200-day moving average is $12.94. Benitec Biopharma has a twelve month low of $7.05 and a twelve month high of $17.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.80 and a current ratio of 14.80. The stock has a market capitalization of $354.11 million, a price-to-earnings ratio of -8.93 and a beta of 0.37.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.12. Sell-side analysts anticipate that Benitec Biopharma will post -1.48 earnings per share for the current year.

Institutional Investors Weigh In On Benitec Biopharma

Several hedge funds have recently bought and sold shares of BNTC. Suvretta Capital Management LLC increased its stake in shares of Benitec Biopharma by 1.5% during the fourth quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company's stock worth $113,165,000 after purchasing an additional 130,956 shares during the period. Franklin Resources Inc. grew its holdings in Benitec Biopharma by 269.0% in the 4th quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock valued at $37,123,000 after buying an additional 2,142,643 shares in the last quarter. Janus Henderson Group PLC increased its position in Benitec Biopharma by 198.5% during the 4th quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock worth $33,268,000 after buying an additional 1,739,904 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Benitec Biopharma by 134.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock worth $24,913,000 after buying an additional 1,131,129 shares in the last quarter. Finally, Infinitum Asset Management LLC lifted its holdings in shares of Benitec Biopharma by 435.7% during the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock worth $14,636,000 after buying an additional 915,000 shares in the last quarter. 52.19% of the stock is currently owned by institutional investors and hedge funds.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.